258 related articles for article (PubMed ID: 32958578)
1. Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in
Pascual J; Lim JSJ; Macpherson IR; Armstrong AC; Ring A; Okines AFC; Cutts RJ; Herrera-Abreu MT; Garcia-Murillas I; Pearson A; Hrebien S; Gevensleben H; Proszek PZ; Hubank M; Hills M; King J; Parmar M; Prout T; Finneran L; Malia J; Swales KE; Ruddle R; Raynaud FI; Turner A; Hall E; Yap TA; Lopez JS; Turner NC
Cancer Discov; 2021 Jan; 11(1):92-107. PubMed ID: 32958578
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Dent S; Cortés J; Im YH; Diéras V; Harbeck N; Krop IE; Wilson TR; Cui N; Schimmoller F; Hsu JY; He J; De Laurentiis M; Sousa S; Drullinsky P; Jacot W
Ann Oncol; 2021 Feb; 32(2):197-207. PubMed ID: 33186740
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
[TBL] [Abstract][Full Text] [Related]
4. Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Dickler MN; Saura C; Richards DA; Krop IE; Cervantes A; Bedard PL; Patel MR; Pusztai L; Oliveira M; Cardenas AK; Cui N; Wilson TR; Stout TJ; Wei MC; Hsu JY; Baselga J
Clin Cancer Res; 2018 Sep; 24(18):4380-4387. PubMed ID: 29793946
[No Abstract] [Full Text] [Related]
5. ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.
Chen JW; Jacot W; Cortés J; Krop IE; Dent S; Harbeck N; De Laurentiis M; Diéras V; Im YH; Stout TJ; Schimmoller F; Savage HM; Hutchinson KE; Wilson TR
Mol Oncol; 2023 Oct; 17(10):2000-2016. PubMed ID: 36892268
[TBL] [Abstract][Full Text] [Related]
6. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
7. Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers.
Hutchinson KE; Chen JW; Savage HM; Stout TJ; Schimmoller F; Cortés J; Dent S; Harbeck N; Jacot W; Krop I; Trabucco SE; Sivakumar S; Sokol ES; Wilson TR
Genome Med; 2023 Apr; 15(1):28. PubMed ID: 37101291
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
Darrigues L; Pierga JY; Bernard-Tessier A; Bièche I; Silveira AB; Michel M; Loirat D; Cottu P; Cabel L; Dubot C; Geiss R; Ricci F; Vincent-Salomon A; Proudhon C; Bidard FC
Breast Cancer Res; 2021 Mar; 23(1):31. PubMed ID: 33676547
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
Tolaney SM; Toi M; Neven P; Sohn J; Grischke EM; Llombart-Cussac A; Soliman H; Wang H; Wijayawardana S; Jansen VM; Litchfield LM; Sledge GW
Clin Cancer Res; 2022 Apr; 28(8):1500-1506. PubMed ID: 35121623
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
O'Leary B; Cutts RJ; Huang X; Hrebien S; Liu Y; André F; Loibl S; Loi S; Garcia-Murillas I; Cristofanilli M; Bartlett CH; Turner NC
J Natl Cancer Inst; 2021 Mar; 113(3):309-317. PubMed ID: 32940689
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2- Advanced/Metastatic Breast Cancer.
Seki H; Sakurai T; Maeda Y; Oki N; Aoyama M; Yamaguchi R; Tokuda T; Kaburagi T; Okumura T; Karahashi T; Nakajima K; Higeta K; Shimizu K
In Vivo; 2019; 33(6):2037-2044. PubMed ID: 31662535
[TBL] [Abstract][Full Text] [Related]
15. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
[TBL] [Abstract][Full Text] [Related]
16. Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.
Moore HM; Savage HM; O'Brien C; Zhou W; Sokol ES; Goldberg ME; Metcalfe C; Friedman LS; Lackner MR; Wilson TR
Mol Cancer Ther; 2020 Jan; 19(1):292-303. PubMed ID: 31534012
[TBL] [Abstract][Full Text] [Related]
17. Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger F; Marce M; Delaloge S; Hardy-Bessard AC; Bachelot T; Bièche I; Pradines A; De La Motte Rouge T; Canon JL; André F; Arnould L; Clatot F; Lemonnier J; Marques S; Bidard FC;
BMJ Open; 2022 Mar; 12(3):e055821. PubMed ID: 35241469
[TBL] [Abstract][Full Text] [Related]
18. Phase II Study of Taselisib in
Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.
Shariati M; Evans KW; Zheng X; Bristow CA; Ng PK; Rizvi YQ; Tapia C; Yang F; Carugo A; Heffernan TP; Peoples MD; Tripathy D; Meric-Bernstam F
Oncogene; 2021 Jul; 40(26):4425-4439. PubMed ID: 34108622
[TBL] [Abstract][Full Text] [Related]
20. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
